SAN ANTONIO, Oct. 30, 2017 /PRNewswire/ -- Invitae (NYSE:
NVTA), one of the fastest growing genetic information companies, is
presenting validation data for a novel, NGS-based preimplantation
genetic screening (PGS) technology that accurately identifies
certain chromosomal abnormalities potentially missed on other PGS
platforms. In addition, company researchers are sharing data
suggesting that if initial PGS testing yields no results, a second
biopsy may provide actionable information. These studies are among
the seven being presented by researchers from Good Start Genetics,
now part of Invitae, at the American Society for Reproductive
Medicine (ASRM) 2017 Scientific Congress & Expo in San Antonio.
![Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation) Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)](https://mma.prnewswire.com/media/592684/Invitae_Corporation_Logo.jpg)
Currently, most NGS-based PGS technologies are limited in that
they cannot detect all forms of triploidy, which is the presence of
three, instead of two, copies of each of the 23 chromosomes in an
embryo. Good Start Genetics' novel NGS-based approach utilizes
single nucleotide polymorphism (SNP) analysis to detect all forms
of triploidy. In addition, the technology can identify haploidy and
many cases of uniparental isodisomy, two additional types of
chromosome abnormalities that may be missed on other PGS
platforms.
"This screening approach is the first of its kind, overcoming
previous challenges in identifying triploidy and offering patients
and clinicians the ability to screen successfully for more of
the chromosome abnormalities that so often lead to
miscarriage," said Robert Nussbaum,
chief medical officer of Invitae. "Ensuring patients have as much
information as possible about their embryos prior to transfer can
help patients and their clinicians maximize the chance of each IVF
transfer to result in a healthy pregnancy."
The new technique will be added to the company's EmbryVu™
testing service, making it the first NGS-based PGS platform that
can identify key chromosomal abnormalities including haploidy,
triploidy and some forms of tetraploidy and UPiD.
A video overview of the study is available at
www.postertalks.com/conferences/asrm-2017-scientific-congress-expo/p-426.
Retesting no-call biopsies may help identify and preserve
healthy embryos
Additional data presented at the meeting showed that embryos for
which initial PGS testing yields no information may simply need a
second round of testing and the majority will be found to be
healthy embryos suitable for transfer. Greater than 97% of biopsies
submitted for reanalysis yielded actionable results on the second
biopsy, and more than half of those embryos showed no
abnormalities.
"PGS can help identify healthy embryos during IVF. This data
shows that if initial testing comes back with a no-call result, a
second test is very likely to provide information, with most of
those embryos showing no chromosomal abnormalities," said Dr.
Nussbaum. "There are a number of factors that could contribute to
an initial PGS biopsy returning no actionable results, from biopsy
technique to the number of cells removed to storage, or another
technical assay step. This study shows those no-result findings
should not be considered a final answer, and taking the time to
re-biopsy may help prevent the stress of choosing to transfer an
embryo without information or classifying as abnormal an embryo
that could lead to a healthy pregnancy."
A video overview of the study is available
www.postertalks.com/conferences/asrm-scientific-conference/p-478.
Full research presentation schedule
Wednesday, November 1, 2017 at
7:00 AM CT:
- Poster #422: Validation of a novel copy number variant
detection algorithm for CFTR from targeted next generation
sequencing data | Presenting author Katya
Kosheleva, PhD, Good Start Genetics
- Poster #423: Identification of polyploid embryos using a
targeted NGS-based preimplantation genetic screening assay |
Presenting author Nicole Faulkner,
PhD, FACMG, Good Start Genetics
- Poster #426: Targeted next generation sequencing-based PGS can
enable detection of uniparental isodisomy, familial relationships,
and polyploidy | Presenting author Mark
Umbarger, PhD, Good Start Genetics
- Poster #461: Aneuploidy rates in day 5 vs day 6 biopsies |
Presenting author Nicole Faulkner,
PhD, FACMG, Good Start Genetics
- Poster #468: Aneuploidy rates in embryos generated from fresh
versus frozen donor oocytes | Presenting author Charlene Alouf, PhD, Good Start Genetics
- Poster #478: Re-biopsied PGS embryos yield actionable results |
Presenting author Dana Neitzel, MS,
CGC, Good Start Genetics
- Poster #479: FMR1 AGG testing in infertility setting: does the
information change reproductive decision-making? | Presenting
author Dana Neitzel, MS, CGC, Good
Start Genetics
Additional information on the ASRM 2017 Scientific Congress
& Expo is available at scientific.asrmcongress.org.
Invitae's reproductive genetics products, which include Good
Start Genetics' GeneVu, EmbryVu and VeriYou, provide
preimplantation genetic screening and carrier screening to offer
comprehensive and flexible testing options that help a wider range
of couples find their paths to pregnancy at significantly lower
costs. Good Start Genetics became part of Invitae in August 2017.
About Invitae
Invitae Corporation (NYSE: NVTA) is one
of the fastest growing genetic information companies in
the United States. Invitae
Corporation's mission is to bring comprehensive genetic information
into mainstream medical practice to improve the quality of
healthcare for billions of people. Invitae's goal is to aggregate
the world's genetic tests into a single service with higher
quality, faster turnaround time, and lower prices. For more
information, visit our website at invitae.com.
Safe Harbor Statements
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
relating to Good Start Genetics' PGS technology and that it can
accurately identify certain chromosomal abnormalities potentially
missed on other PGS platforms; and research data which suggests
that retesting no-call biopsies may help identify and preserve
healthy embryos. Forward-looking statements are subject to risks
and uncertainties that could cause actual results to differ
materially, and reported results should not be considered as an
indication of future performance. These risks and uncertainties
include, but are not limited to: risks associated with the
company's ability to use rapidly changing genetic data to interpret
test results accurately and consistently; laws and regulations
applicable to the company's business; the company's limited
experience with respect to acquisitions and its ability to
integrate newly acquired companies successfully into its existing
business; the company's history of losses; the company's ability to
compete; and the other risks set forth in the company's filings
with the Securities and Exchange Commission, including the risks
set forth in the company's Quarterly Report on Form 10-Q for the
quarter ended June 30, 2017. These
forward-looking statements speak only as of the date hereof, and
Invitae Corporation disclaims any obligation to update these
forward-looking statements.
NOTE: Invitae and the Invitae logo are trademarks of Invitae
Corporation. All other trademarks and service marks are the
property of their respective owners.
Contact:
Laura D'Angelo
pr@invitae.com
314-920-0617
View original content with
multimedia:http://www.prnewswire.com/news-releases/invitae-presents-validation-of-a-novel-ngs-based-preimplantation-genetic-screening-technology-to-identify-the-most-frequent-chromosomal-causes-of-miscarriage-300545264.html
SOURCE Invitae Corporation